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ABSTRACT
Introduction: The fundus examination is a
non-invasive evaluation of the microcirculation of the
retina. The aim of the present study is to develop and
validate (reliability and validity) the ALTAIR software
platform (Automatic image analyser to assess retinal
vessel calibre) in order to analyse its utility in different
clinical environments.
Methods and analysis: A cross-sectional study in
the first phase and a prospective observational study
in the second with 4 years of follow-up. The study
will be performed in a primary care centre and will
include 386 participants. The main measurements will
include carotid intima-media thickness, pulse wave
velocity by Sphygmocor, cardio-ankle vascular index
through the VASERA VS-1500, cardiac evaluation by a
digital ECG and renal injury by microalbuminuria and
glomerular filtration. The retinal vascular evaluation
will be performed using a TOPCON TRCNW200 non-
mydriatic retinal camera to obtain digital images of
the retina, and the developed software (ALTAIR) will
be used to automatically calculate the calibre of the
retinal vessels, the vascularised area and the
branching pattern. For software validation, the
intraobserver and interobserver reliability, the
concurrent validity of the vascular structure and
function, as well as the association between the
estimated retinal parameters and the evolution or
onset of new lesions in the target organs or
cardiovascular diseases will be examined.
Ethics and dissemination: The study has been
approved by the clinical research ethics committee of
the healthcare area of Salamanca. All study
participants will sign an informed consent to agree to
participate in the study in compliance with the
Declaration of Helsinki and the WHO standards for
observational studies. Validation of this tool will
provide greater reliability to the analysis of retinal
vessels by decreasing the intervention of the
observer and will result in increased validity through
the use of additional information, especially in the
areas of vascularisation and vessel branching
patterns.
Trial registration number: Clinical Trials.gov
Identifier: NCT02087605.
INTRODUCTION
Fundus examination is a non-invasive evalu-
ation of the retinal microcirculation and of
the vascular damage caused by multiple car-
diovascular risk factors. Different tools have
been developed to evaluate the thickness of
the retinal arteries and veins,1–7 however, all
of them require intervention of an observer
to some extent. Moreover, the techniques
and tools that are currently applied are
manual or semiautomatic in nature, for
which the observer has an important influ-
ence, thus providing limited information.
In population studies, an association has
been found between the calibre of the retinal
vessels and arterial hypertension,8 left ven-
tricular hypertrophy,9 metabolic syndrome,10
stroke11 and coronary heart disease,12 espe-
cially in women.13 However, other studies
disagree and show contradictory results
Strengths and limitations of this study
▪ A new software for retinal vessels evaluation will
be developed, the automatic image analyser to
assess retinal vessel calibre (ALTAIR) platform.
▪ A complete evaluation of retinal vascularisation,
including automatically calculating the calibre of
the retinal vessels, the vascularised area and the
branching pattern will be performed.
▪ The interobserver and intraobserver reliability in
determining the calibre of arterial and venous
vessels, the vascularised surface and branching
patterns using the ALTAIR software platform will
be performed.
▪ The concurrent validity of the ALTAIR software
platform, by analysing the relationship between
retinal parameters and other parameters of vas-
cular structure and function, will be performed.
▪ The design of the study during the first phase is
transversal; as a result, causality relations cannot
be derived, that is, only the associations among
the analysed variables can be performed.
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regarding the evolution of the arteriosclerotic lesion and
the calibre of the retinal vessels.14–16 In this way, Cuspidi
et al17 and Masaidi et al18 failed to detect an association
between the calibre of the retinal vessels and target organ
injuries (cardiac, vascular and renal) in studies of two
hypertensive populations. However, Torres et al19
reported a negative association between carotid intima-
media thickness (IMT) and the thickness of the retinal
arteries but a positive association with the veins.
Recently, our group developed and validated a semi-
automatic tool, the arteriovenous index calculator, to
evaluate the vascular calibre of the retinal vessels,20
with reduced influence of the observer. This tool
showed high reliability when measuring the calibre of
the retinal vessels with an intraclass correlation coeffi-
cient (ICC) for intraobserver and interobserver greater
than 0.96 for veins, arteries and the arteriovenous ratio
(AVR). These measures, especially the venous calibre
and the AVR, were also shown to be independent vari-
ables associated with estimated cardiovascular risk,
according to the Framingham scale and the microvascu-
lar kidney lesions evaluated according to the level of
microalbuminuria. This positive association between the
cardiovascular risk and the venous calibre is in line
with several published studies showing an association
between the AVR and the risk of coronary heart
disease.12 13 21 However, longitudinal studies with a
greater number of patients would help to clarify the
discrepancies among previously published studies on
cardiovascular risk, and vascular structure and function.
Moreover, it should not be forgotten that these tools
provide less information than retinal imaging on the
thickness of the arteries and veins, their branching pat-
terns and the vascularised areas, which may be relevant
for evaluating the status of the vascular tree and may
be the cause of some of the discrepancies previously
reported.
A new and different approach to the study of the vascu-
lar systems is the characterisation of the blood vessel pat-
terns in the normal circulation of the human retina.22
With this method, the distribution of the branching of
the vascular system in a two-dimensional space can be
analysed, and the geometrical complexity of the branch-
ing and the density of the retinal vessels can be quanti-
fied.23 Indeed, the current scientific literature contains a
number of publications on this subject.24–27
In the present study, a novel software platform for
image processing of the structural properties of the
vessels is proposed using a human fundus red-free
camera. The “Automatic image analyser to assess retinal
vessel calibre” (ALTAIR) software platform employs ana-
lytical methods and artificial intelligence (AI) algo-
rithms to detect the retinal parameters of interest. The
sequence of the algorithms consists of a new method-
ology that can be used to determine the properties of
the veins and arteries of the retina; together, this system
unifies all of the methods for automation of the measur-
ing processes of retinal vessels.
Therefore, the general aim of the present study is the
development and validation (reliability and validity) of
the ALTAIR software platform in order to analyse its
utility in different clinical settings. The following specific
objectives will be studied:
1. Evaluation of interobserver and intraobserver reliabil-
ity in determining the calibre of arterial and venous
vessels, the vascularised surface and branching pat-
terns using the ALTAIR software platform.
2. Evaluation of the concurrent validity of the ALTAIR
software platform, in different populations and ethni-
cities, by analysing the relationship between retinal
parameters and other parameters of vascular struc-
ture and function, including carotid IMT, pulse wave
velocity (PWV) and the cardioankle vascular index
(CAVI), as well as injuries in other target organs and
the cardiovascular risk.
3. Evaluation of the evolution of target organ injuries
and cardiovascular morbidity, and mortality accord-
ing to the vascularisation parameters of the retina
determined using the ALTAIR software platform.
METHOD AND ANALYSIS
Study design
The first phase will be a cross-sectional study aimed at
validating the developed tool. Subsequently, the second
phase will consist of a prospective observational study
with annual follow-up evaluations over 4 years. The study
will be developed in a primary healthcare setting.
Subjects
Study population
The population under study will consist of participants
from 35 to 74 years of age with a cardiovascular risk
factor according to the 2013 European Society of
Hypertension/European Society of Cardiology
Guidelines.28 Participants are excluded due to the fol-
lowing criteria: psychic or cognitive disorders that inter-
fere with the established requisites of the protocol;
non-collaborative attitude; educational or comprehen-
sive limitations; and severe comorbidities with a
12-month likelihood of life-threatening complications.
A consecutive sampling of all patients sent to the
research unit for cardiovascular risk evaluation will be
performed, and those complying with the inclusion and
exclusion criteria will be asked to participate until the
estimated sample size is achieved. The participants will
be mostly Caucasian, the majority ethnic group among
patients attending in the health centre; however, at least
50 ethnic minority participants, to give more validity to
the tool, will be included.
Sample size
The sample size has been set to detect a correlation
coefficient among the PWV, the gold standard measure
of arterial stiffness, and the retinal parameters of 0.15,
with an α risk of 0.05 and a β risk of 0.20 and a 10%
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estimated loss regarding the difficulty of the technique
or dropout on follow-up. As a result, a total of 386
patients will be included in the study. This number of
patients will be adequate to detect a difference of 1 m/s
on the PWV among the AVR tertiles, considering a SD of
2.22 m/s with an α risk of 0.05 and a β risk of 0.20.
Variables and measurement instruments
General and potentially effect-modifying variables, such
as age, gender, occupation, smoking, alcohol consump-
tion, personal history and drug use will be documented.
Laboratory determinations
Venous blood sampling will be performed between 8:00
and 9:00 after the individuals have fasted, abstained
from smoking, and abstained from the consumption of
alcohol and caffeinated beverages for the previous 12 h.
Fasting plasma glucose, creatinine, uric acid, serum total
cholesterol, high-density lipoprotein (HDL)-cholesterol
and triglyceride concentrations will be measured using
standard enzymatic automated methods. Low-density
lipoprotein (LDL) cholesterol will be estimated by the
Friedewald equation when the direct parameter is not
available. Glycated haemoglobin will be measured
with an immune-turbidimetric assay. High sensitive C
reactive protein levels and fibrinogen concentrations will
be determined by immunoturbidimetric assay. Blood
samples will be collected in the health centre, and will
be analysed at the University Hospital of Salamanca in
external quality assurance programmes of the Spanish
Society of Clinical Chemistry and Molecular Pathology.
Anthropometric measurements
Body weight will be determined on two occasions
using a homologated electronic scale (Seca 770; Medical
Scale and Measurement Systems, Birmingham, UK) fol-
lowing due calibration (precision±0.1 kg), with the
patient wearing light clothing and shoeless. These read-
ings will be rounded to 100 g. Height will be measured
with a portable system (Seca 222; Medical Scale and
Measurement Systems, Birmingham, UK), recording the
average of two readings, and with the patient shoeless in
the standing position. The values will be rounded to the
closest centimetre. Body mass index (BMI) will be calcu-
lated as weight (kg) divided by height squared (m2). A
value of >30 kg/m² will be taken to define obesity. Waist
circumference will be measured using a flexible gradu-
ated measuring tape with the patient in the standing
position without clothing. The upper border of the iliac
crests will be located, and the tape will be wrapped
around above this point, parallel to the floor, ensuring
that it will be adjusted without compressing the skin.
Adiposity indices, waist-height and waist-hip, will also be
calculated.
Office or clinical blood pressure
Office blood pressure measurement will involve three
measurements of systolic blood pressure (SBP) and
diastolic blood pressure (DBP), using the average of the
last two, with a validated OMRON model M10-IT sphyg-
momanometer (Omron Health Care, Kyoto, Japan), by
following the recommendations of the European Society
of Hypertension.29 Pulse pressure will be estimated with
the mean values of the second and third measurements.
PWV and central and peripheral augmentation index
These parameters will be estimated using the
SphygmoCor System (AtCor Medical Pty Ltd, Head
Office, West Ryde, Australia). With the patient sitting
and resting his/her arm on a rigid surface, pulse wave
analysis will be performed with a sensor in the radial
artery, using mathematical transformation to estimate
the aortic pulse wave. Central augmentation index
(CAIx) will be estimated from aortic wave morphology
using the following formula: increase in central pres-
sure×100/pulse pressure, and it will be adjusted for
heart rate at 75 bpm. Peripheral augmentation index
(PAIx) is a measurement taken directly from the late sys-
tolic shoulder of the peripheral arterial waveform, and is
defined as the ratio of the difference between the
second peak and diastolic pressure to the difference
between the first peak and diastolic pressure,30 it is age-
dependent, and could be a useful index of vascular
aging.31 PAIx will be calculated as follows: (second peak
SBP2−DBP/first peak SBP−DBP)×100 (%), it will be cor-
rected for heart rate at 75 bpm and it will be reported as
PAIx75. Carotid and femoral artery pulse waves will be
analysed, with the patient in a supine position, using the
SphygmoCor System (Vx pulse wave velocity), estimating
the delay as compared to the ECG wave and calculating
PWV. Distance measurements will be taken with a measur-
ing tape from the sternal notch to the carotid and
femoral arteries at the sensor location and will be multi-
plied by 0.8. Subclinical organ damage of PWV will be
defined as a carotid–femoral PWV >10 m/s.28 32
Assessment of vascular structure by carotid IMT
Carotid ultrasound to assess C-IMT will be performed by
two investigators trained for this purpose before starting
the study. A Sonosite Micromax ultrasound device
paired with a 5–10 MHz multifrequency high-resolution
linear transducer with Sonocal software will be used for
performing automatic measurements of carotid IMT in
order to optimise reproducibility. Measurements will be
made of the common carotid after the examination of a
10 mm longitudinal section at a distance of 1 cm from
the bifurcation, performing measurements in the prox-
imal and in the distal wall in the lateral, anterior and
posterior projections, following an axis perpendicular to
the artery to discriminate two lines, one for the intima-
blood interface and the other for the media-adventitious
interface. A total of 6 measurements will be obtained of
the right carotid and another 6 of the left carotid, using
average values (average carotid IMT) and maximum
values (maximum carotid IMT) automatically calculated
by the software.33 The measurements will be obtained
Garcia-Ortiz L, et al. BMJ Open 2014;4:e006144. doi:10.1136/bmjopen-2014-006144 3
Open Access
with the participant lying down, with the head extended
and slightly turned opposite to the examined carotid
artery. The reliability was evaluated before the study
began, using the intraclass correlation coefficient, which
showed values of 0.974 (95% CI 0.935 to 0.990) for
intraobserver agreement on repeated measurements in
20 participants, and 0.897 (95% CI 0.740 to 0.959) for
interobserver agreement. According to the Bland-
Altman analysis, the mean difference for intraobserver
agreement (95% limits of agreement) was 0.022 (95%
CI −0.053 to 0.098) and intraobserver agreement was
0.012 (95% CI −0.034 to 0.059). The average IMT will
be considered abnormal if it measures >0.90 mm, or if
there are atherosclerotic plaques with a diameter of
1.5 mm or a focal increase of 0.5 mm or 50% of the
adjacent IMT.28
CAVI and ankle-brachial index
CAVI and ankle-brachial index (ABI) will be measured
using Vasera device VS-1500 (Fukuda Denshi). The PWV
will be calculated, as well as CAVI, which gives a more
accurate calculation of the atherosclerosis degree. CAVI
integrates cardiovascular elasticity derived from the
aorta to the ankle pulse velocity through an oscillo-
metric method; it is used as a good measure of vascular
stiffness and does not depend on blood pressure.34 CAVI
values will be automatically calculated by substituting the
stiffness parameter ß in the following equation to detect
the vascular elasticity and the cardioankle PWV: stiffness
parameter β=2ρ×1/(Ps–Pd)×ln (Ps/Pd)×PWV2, where ρ
is the blood density, Ps and Pd are SBP and DBP in
mm Hg, and the PWV is measured between the aortic
valve and ankle. The average coefficient of the variation
of the CAVI is less than 5%, which is small enough for
clinical use and confirms that CAVI has favourable repro-
ducibility.35 CAVI and ABI will be measured at rest. For
the study, the lowest ABI and the highest CAVI and PWV
obtained will be considered.
Renal assessment
Kidney damage will be assessed by measuring estimated-
glomerular filtration rate using the CKD-EPI (chronic
kidney disease epidemiology collaboration)36 equation
and proteinuria, as assessed by the albumin/creatinine
ratio following the criteria of the 2013 European Society
of Hypertension/European Society of Cardiology
Guidelines.28 Subclinical organ damage will be defined
as a glomerular filtration rate below 30–60 mL/min/
1.73 m2 or microalbuminuria (30–300 mg/24 h), or
albumin–creatinine ratio (30–300 mg/g; 3.4–34 mg/
mmol; preferably on morning spot urine). Renal disease
will be defined as a glomerular filtration rate <30 mL/
min/1.73 m2 (body surface area), proteinuria (>300 mg/
24 h), or albumin/creatinine ratio >300 mg/24 h.28
Cardiac assessment
Electrocardiographic examination will be performed
using a General Electric MAC 3.500 ECG System
(Niskayuna, New York, USA), which automatically
measures wave voltage and duration, and estimates
the criteria of the Cornell voltage-duration product
(Cornell VDP).37 Electrocardiographic left ventricular
hypertrophy will be defined as a Sokolow-Lyon index
>3.5 mV; RaVL >1.1 mV, Cornell voltage duration
product >244 mV×ms or RaVL >1.1 mV.28
Cardiovascular risk assessment
Cardiovascular risk will be estimated using the score of
the 2013 European Society of Hypertension/European
Society of Cardiology Guidelines28 and the risk equation
(D’Agostino scale) based on the Framingham study.38
Risk factors used include age, sex, total cholesterol, high-
density lipoprotein cholesterol (HDL-C) and SBP as
quantitative variables, and drug treatment for hyperten-
sion, smoking and history of diabetes mellitus as dichot-
omous variables.
Retinal vascular evaluation
Using a non-mydriatic retinography, TOPCON TRC NW
200, (Topcon Europe BC, Capelle a/d Ijssel, The
Netherlands) in the sitting position, a trained nurse will
get nasal and temporal images centred in the papilla.
Then, using the specific software developed (ALTAIR),
the retinal vessels’ thickness, the AVR, the area vascu-
larised and the pattern of branching will be automatic-
ally calculated.
Development of the ALTAIR platform: Automatic image
analyser to assess retinal vessel calibre.
The platform, called ALTAIR “Automatic image ana-
lyser to assess retinal vessel calibre”, makes use of a
methodology divided in different stages, which are
described below, to determine the characteristics of
interest of the veins and arteries of the retina. This
methodology uses AI techniques and analytical algo-
rithms to discover retinal parameters of interest.
The methodology is separated into two phases: (1)
Digitisation of the retina, in which the different mea-
sures of the eye image are recognised. Here a data struc-
ture is created, which makes it possible to represent and
process the retina. This phase is subdivided into the fol-
lowing steps as discussed below: load image and eye
detection, processing, detection and segmentation. (2)
Measurements with which we work with retinas, which
have been previously identified. This phase includes
extraction of knowledge and manual correction, or
expert knowledge, if necessary.
Digitisation of the retina: To perform this phase, the fol-
lowing steps are necessary:
1. Load image and eye detection: The platform will
automatically try to determine which eye (left or
right) is the image, based on the detection of the
macula. In this step, if the automatic detection has
been wrong, the supervisor can modify this value by
simply clicking on the correct eye.
2. Processing: In this step, the noise is reduced, contrast is
improved, blurriness corrected and edges sharpened.
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Some of these actions can be carried out at the hard-
ware level, which is to say, with the features included
with the camera. During the testing, retinography will
be performed using a Topcon TRC NW 200 non-
mydriatic retinal camera, obtaining nasal and temporal
images centred on the disk.
3. Detection limits: In this step, the platform is capable
of locating the disk and identifying the centre and
edges of the retina (figure 1). The identification of
the papilla is vital since it helps as the starting
point for the detection and identification of the
different blood vessels. The platform builds a data
structure that identifies each part of the retina based
on the matrices of colours representing the images
obtained. In this step, image processing techni-
ques24 26 will be used to detect intensity based on the
boundaries of the structures.
4. Segmentation: In order to detect the limits, it
becomes necessary to carry out a process of image seg-
mentation. Segmentation is the process that divides
an image into regions or objects of which the pixels
have similar attributes. Each segmented region typic-
ally has a physical significance within the image. It is
one of the most important processes in an automated
vision system because it makes it possible to extract
the objects from the image for subsequent description
and recognition.39–41 This step can be considered the
heart of the methodology proposed and used in the
platform, and performs the following actions:
A. Identification of vessels. Blood vessels are iden-
tified in the image by thresholding techniques.
Their purpose is to remove pixels where the
structuring element does not enter, in this case
the blood vessels. The platform offers here a
number of useful options for experts: threshold
vessels, in order to modify the threshold level
automatically taken, to new vessel detection.
Recalculate vessels, recalculate the vessels
taking as the threshold established with the pre-
vious parameter. Pencil/eraser thickness: sets
thickness to draw or erase lines/vessels or to
switch vessels. Connect: selecting this option
allows the user to interact with the overall
image of the retina, connecting those vessels in
which the structure has been divided as they
were an undetected section.
B. Structure of vessel. At the end of this stage the
entire arteriovenous tree is stored in a struc-
tured way, making it possible to know not only
if a vessel passes through a point or not, but
through which point each vessel passes, which
one is its parent, etc.
C. Cataloguing of veins and arteries (figure 2). In
this step the platform detects whether a vessel
is a vein or an artery; the main branch of the
vessel is taken. In this step different classifiers
based on AI as decision trees and Bayesian net-
works42 are applied.
Measurements
In this second phase, the results obtained are presented.
The platform can display the following measures: thick-
ness of the veins in μm, artery thickness in μm, AVR
(ratio between the thickness of the arteries and veins),
veins area in square μm, artery area in square μm, area
of all vessels in square μm and radio papilla in
millimeters.
The platform also generates internally combined para-
meters through quadrants and circles. These values are
visible when it comes to exporting the CSV files either
individually or together with other existing processed
database image values taken earlier.
Results of its validity analysis must be consistent with
the findings from researches focused on cardiovascular
risk estimation as well as evaluation of target organ
damage. The results obtained during the use of the plat-
form will be connected and used to extract additional
information by using reasoning models such as case-
based reasoning (CBR).43 44
In conclusion, the platform is robust to changes in
the appearance of retinal fundus images typically
encountered in clinical environments, and is proposed
as a unified platform to connect all the methods needed
to automate all processes of measurement on the
retinas.
Figure 1 Detection and identification of vessels steps: locating
the disk and identifying the centre and edges of the retina.
Figure 2 Detection and identification of vessels steps:
cataloguing of veins and arteries.
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Retinal software validation
To validate the retinal software platform, the following
steps will be completed by the evaluators after previous
training in imaging appreciation.
▸ Evaluation of the reliability or precision
1. Intraobserver variability: To evaluate the measure-
ment repeatability, the operator must measure the
same image of an individual on at least two occasions.
To this end, an operator will measure 100 images of
a random subsample of 50 patients with a 1-week dif-
ference between the two measurements. In this case,
the operator and the analysed images will be the
same on both days, and the information from the
previous measurement will be unknown.
2. Interobserver variability: To evaluate the reproducibil-
ity of the measurement system, an operator other
than the one who completed the assessment in phase
1 will evaluate the same 100 images previously ana-
lysed. The information from the results obtained in
the previous phase will be unknown to this operator,
and both operators will have the same experience in
the subject and pertaining to the use of the software.
Furthermore, both operators will receive the same
preparatory training.
▸ Evaluating the validity (accuracy)
1. To assess the degree of agreement between ALTAIR
and the AV Index calculator software (1) previously
validated by us, the evaluation of 100 images will be
performed using both tools. In this way, we will be
able to demonstrate that the new method, apart from
providing the same results, is more objective and
faster in elaborating the results.
2. The measurement validity will be analysed in a total
sample of 386 participants and 772 retinographies in
regard to the relationship between the results of the
carotid IMT as a measurement of vascular structure,
the PWV, the gold standard measure of arterial stiff-
ness, the CAVI, kidney function, electrocardiographic
parameters and the estimated cardiovascular risk
using different scales.
3. The association between different estimated para-
meters of the retina with the evolution or onset of new
lesions in the target organs will be analysed, as well as
any cardiovascular events that occur during the 4-year
follow-up of the second phase of this project.
Statistical analysis
The data corresponding to quantitative variables with a
normal distribution will be presented with the mean and
SD and with the median and an IQR if the distribution is
asymmetric, while the qualitative variables will be pre-
sented according to the distribution of the frequencies.
Normality will be evaluated with the Kolmogorov-Smirnov
test. The Pearson’s χ2 test will be used to analyse associa-
tions between the qualitative variables. The mean compari-
son, in the case of two groups, will be performed using the
Student’s t test for independent samples and, in the case
of larger groups, will be performed using the ANOVA test.
Post hoc contrasts will be performed with the least signifi-
cant difference (LSD) method and an α value <0.05.
Repeated data will be analysed with the Student’s t test for
paired data. The relationship between quantitative vari-
ables will be analysed according to the Pearson’s or
Spearman’s correlation coefficient, depending on the type
of distribution being considered. Finally, a multivariate
analysis with multiple lineal regressions will be performed
to analyse the association of the retinal parameters gener-
ated by ALTAIR with the vascular structure and function.
To contrast the hypothesis, an α risk of 0.05 will be set as
the limit of statistical significance. Statistical analysis will be
performed using SPSS/PC+ software V.20.0.
For validation of the retinal software, we will evaluate
the measurements of artery and vein thickness, vascu-
larised surfaces and branching patterns from the three
phases of validation, and theICC will be calculated as a
comparative method. Using the Bland-Altman method,
the limits of agreement between the measurements of
the observers will be evaluated. The κ agreement coeffi-
cient will be analysed to categorise the variable. This
coefficient will allow us to evaluate the degree of agree-
ment between the two methods. The accordance validity
will also be analysed via correlation and multiple regres-
sion analysis, by evaluating the degree of association
with other parameters of vascular structure and func-
tion, and target organ injury.
Project schedule
This project will be on a 5-year plan, with the aim of
developing and validating the ALTAIR software platform
during the first year. Subsequently, a 4-year follow-up
study will be performed to evaluate the evolution of
target organ injuries, as well as the cardiovascular risk
on the analysed retinal vascularisation parameters, that
is, the artery and vein thickness, the vascularised surface
and the branching patterns. An exhaustive evaluation of
the participant will be performed at baseline and during
the third and fifth years. A short evaluation will be per-
formed during the second and fourth years.
Quality control
In order to ensure data quality, the professionals in
charge of assessment of retinal images and data collec-
tion will receive specific training. Regular external moni-
toring will then be performed to verify adequate
application of methods, both in performing the differ-
ent examinations and collecting the information.
Ethical and legal issues
The study has been approved by the clinical research
ethics committee (CEIC) of the healthcare area of
Salamanca (‘CEIC of Area de Salud de Salamanca’, 29
January 2014). Participants will be required to sign an
informed consent form prior to inclusion in the study, in
accordance with the Declaration of Helsinki.45
Participants will be informed of the objectives of the
project and of the risks and benefits of the examinations
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made. None of the examinations pose life-threatening
risks for the type of participants to be included in the
study. The study includes the obtaining of biological
samples; the study particpants therefore will be informed
in detail. The confidentiality of the recruited participants
will be ensured at all times in accordance with the
provisions of current legislation on personal data protec-
tion (15/1999 of 13 December, LOPD), and the condi-
tions contemplated by Act 14/2007 on biomedical
research.
DISCUSSION
In a previous study performed by our group,20 we identi-
fied a positive association between the cardiovascular
risk, estimated with the Framingham scale, and the
retinal vessel calibre, mainly the venous calibre, and this
association was maintained in the multivariate analysis.
The arterial calibre, which also demonstrated a positive
association, and the AVR, which demonstrated a negative
association, seem to play a less relevant role than the
venous calibre in regard to the cardiovascular risk.
The positive association between the cardiovascular
risk and the venous calibre is in accordance with several
published studies showing an association between the
AVR and coronary heart disease risk.12 13 21 For
example, McGeechan et al21 showed that when including
the arterial and venous thickness, the Framingham
model improved coronary event prediction, but only in
women. This finding was repeated in several studies and
was recently reported in a meta-analysis,13 which seems
to support the notion that microvascular disease could
be more important than coronary heart disease in
women than in men.46 However, these results have been
variable; Wong et al,47 in the Beaver Dam Eye study,
described the lack of an association between the AVR,
cardiovascular morbidity and mortality in the examined
subgroups. In addition, Wang et al48 identified an associ-
ation between venous calibre and coronary death in
men but not in women.
It is likely that some of these discrepancies are due to
the different tools employed for evaluation of the
retinal vessels, as all of these methods are manual or
semiautomatic and, to a greater or lesser degree, are
susceptible to the influence of the observer. The use of
only particular information regarding the vascularisa-
tion of the retina may also influence the results.
However, the ALTAIR software platform resolves these
problems. On the one hand, this platform is practically
an automated tool with low observer influence. In add-
ition, we expect the interobserver and intraobserver
variability to be low and, as a result, the reliability to be
significantly elevated. On the other hand, by using add-
itional information on retinal vascularisation, the vascu-
larised surface, the vascularisation patterns and the
artery and vein thickness, we expect to improve the val-
idity of the tool and clarify the discrepancies reported
in previous studies.
Study limitations
Data will be obtained from patients with a cardiovascular
risk factor, who satisfy the inclusion criteria and who
were referred by a family physician to the research unit
for vascular risk assessment. Thus, this approach uses a
consecutive sampling method with inclusion criteria,
that is, a non-randomised sampling method. However,
the size of the sample may buffer this limitation, and the
real clinical conditions may lead us to a more real situ-
ation than that using more restrictive inclusion criteria
for the study patients. The design of the study during
the first phase is transversal; as a result, causality rela-
tions cannot be derived, that is, only the associations
among the analysed variables can be performed.
Therefore, non-statistically detected associations between
variables may be possible due to the sample size.
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